Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Butyrate triglyceride is used to support or treat colitis based on emerging scientific evidence, particularly from preclinical studies and some early clinical trials. Butyrate is a short-chain fatty acid (SCFA) produced naturally in the colon through microbial fermentation of dietary fibers. It plays a critical role in maintaining colonic health by serving as a primary energy source for colonocytes, modulating inflammation, and supporting the integrity of the gut barrier.

Animal studies have demonstrated that butyrate supplementation can reduce inflammation and promote mucosal healing in models of colitis. The mechanism involves inhibition of nuclear factor-kappa B (NF-κB), reduction of pro-inflammatory cytokines, and enhancement of regulatory T cell responses. Butyrate also helps strengthen tight junctions, reducing gut permeability, which is often increased in colitis.

Clinically, butyrate (often delivered as sodium butyrate enemas or oral formulations) has shown some benefit in small trials for patients with ulcerative colitis, especially those with distal disease. However, butyrate triglyceride—a more palatable and potentially better-absorbed oral form—has not yet been as extensively studied in humans as direct butyrate salts. Preliminary research suggests it could deliver butyrate to the colon more effectively, but large, high-quality clinical trials are lacking.

In summary, while there is a clear scientific rationale and promising early evidence for the use of butyrate triglyceride in colitis, more robust clinical data are needed. Its use is justified by current scientific understanding, though the strength of the evidence is moderate and still developing.

More about butyrate triglyceride
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by butyrate triglyceride

Products containing butyrate triglyceride